259 related articles for article (PubMed ID: 20800383)
1. Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients.
Weber DC; Johanson S; Peguret N; Cozzi L; Olsen DR
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):490-7. PubMed ID: 20800383
[TBL] [Abstract][Full Text] [Related]
2. Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study.
Weber DC; Peguret N; Dipasquale G; Cozzi L
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1578-86. PubMed ID: 19596171
[TBL] [Abstract][Full Text] [Related]
3. Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study.
Hoppe BS; Flampouri S; Su Z; Morris CG; Latif N; Dang NH; Lynch J; Li Z; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):260-7. PubMed ID: 22014950
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy.
Koeck J; Abo-Madyan Y; Lohr F; Stieler F; Kriz J; Mueller RP; Wenz F; Eich HT
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):268-76. PubMed ID: 22079733
[TBL] [Abstract][Full Text] [Related]
5. A planning comparison of dose patterns in organs at risk and predicted risk for radiation induced malignancy in the contralateral breast following radiation therapy of primary breast using conventional, IMRT and volumetric modulated arc treatment techniques.
Johansen S; Cozzi L; Olsen DR
Acta Oncol; 2009; 48(4):495-503. PubMed ID: 19169915
[TBL] [Abstract][Full Text] [Related]
6. Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both?
Aznar MC; Maraldo MV; Schut DA; Lundemann M; Brodin NP; Vogelius IR; Berthelsen AK; Specht L; Petersen PM
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):169-74. PubMed ID: 25754634
[TBL] [Abstract][Full Text] [Related]
7. Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk.
Filippi AR; Ragona R; Piva C; Scafa D; Fiandra C; Fusella M; Giglioli FR; Lohr F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):161-8. PubMed ID: 25863763
[TBL] [Abstract][Full Text] [Related]
8. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma.
Hodgson DC; Koh ES; Tran TH; Heydarian M; Tsang R; Pintilie M; Xu T; Huang L; Sachs RK; Brenner DJ
Cancer; 2007 Dec; 110(11):2576-86. PubMed ID: 17941006
[TBL] [Abstract][Full Text] [Related]
9. Doses to carotid arteries after modern radiation therapy for Hodgkin lymphoma: is stroke still a late effect of treatment?
Maraldo MV; Brodin P; Aznar MC; Vogelius IR; Munck af Rosenschöld P; Petersen PM; Specht L
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):297-303. PubMed ID: 23910709
[TBL] [Abstract][Full Text] [Related]
10. Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy.
Chera BS; Rodriguez C; Morris CG; Louis D; Yeung D; Li Z; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1173-80. PubMed ID: 19386423
[TBL] [Abstract][Full Text] [Related]
11. Clinical implementation of tangential field intensity modulated radiation therapy (IMRT) using sliding window technique and dosimetric comparison with 3D conformal therapy (3DCRT) in breast cancer.
Selvaraj RN; Beriwal S; Pourarian RJ; Lalonde RJ; Chen A; Mehta K; Brunner G; Wagner KA; Yue NJ; Huq SM; Heron DE
Med Dosim; 2007; 32(4):299-304. PubMed ID: 17980832
[TBL] [Abstract][Full Text] [Related]
12. The effect on esophagus after different radiotherapy techniques for early stage Hodgkin's lymphoma.
Jørgensen AY; Maraldo MV; Brodin NP; Aznar MC; Vogelius IR; Rosenschöld PM; Petersen PM; Specht L
Acta Oncol; 2013 Oct; 52(7):1559-65. PubMed ID: 24047340
[TBL] [Abstract][Full Text] [Related]
13. Effect of intensity-modulated pelvic radiotherapy on second cancer risk in the postoperative treatment of endometrial and cervical cancer.
Zwahlen DR; Ruben JD; Jones P; Gagliardi F; Millar JL; Schneider U
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):539-45. PubMed ID: 19427555
[TBL] [Abstract][Full Text] [Related]
14. Radiation-induced second malignancies after involved-node radiotherapy with deep-inspiration breath-hold technique for early stage Hodgkin Lymphoma: a dosimetric study.
Schneider U; Sumila M; Robotka J; Weber D; Gruber G
Radiat Oncol; 2014 Feb; 9():58. PubMed ID: 24548307
[TBL] [Abstract][Full Text] [Related]
15. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate.
Luxton G; Hancock SL; Boyer AL
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):267-84. PubMed ID: 15093924
[TBL] [Abstract][Full Text] [Related]
16. Volumetric intensity-modulated arc therapy vs. conventional IMRT in head-and-neck cancer: a comparative planning and dosimetric study.
Verbakel WF; Cuijpers JP; Hoffmans D; Bieker M; Slotman BJ; Senan S
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):252-9. PubMed ID: 19362244
[TBL] [Abstract][Full Text] [Related]
17. A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk.
Koh ES; Tran TH; Heydarian M; Sachs RK; Tsang RW; Brenner DJ; Pintilie M; Xu T; Chung J; Paul N; Hodgson DC
Radiat Oncol; 2007 Mar; 2():13. PubMed ID: 17362522
[TBL] [Abstract][Full Text] [Related]
18. Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy.
Campbell BA; Hornby C; Cunninghame J; Burns M; MacManus M; Ryan G; Lau E; Seymour JF; Wirth A
Ann Oncol; 2012 May; 23(5):1259-1266. PubMed ID: 21980193
[TBL] [Abstract][Full Text] [Related]
19. Involved Node, Site, Field and Residual Volume Radiotherapy for Lymphoma: A Comparison of Organ at Risk Dosimetry and Second Malignancy Risks.
Murray L; Sethugavalar B; Robertshaw H; Bayman E; Thomas E; Gilson D; Prestwich RJ
Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):401-10. PubMed ID: 25840609
[TBL] [Abstract][Full Text] [Related]
20. Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma.
Maraldo MV; Brodin NP; Vogelius IR; Aznar MC; Munck Af Rosenschöld P; Petersen PM; Specht L
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1232-7. PubMed ID: 22270170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
